Loibl, S. (8 September 2014). PIK3CA mutations are associated with lower rates of pathologic complete response to anti-human epidermal growth factor receptor 2 (HER2) therapy in primary HER2-overexpressing breast cancer. Journal of clinical oncology, 32, . doi:10.1200/JCO.2014.55.7876

"PIK3CA mutations are associated with lower rates of pathologic complete response to anti-human epidermal growth factor receptor 2 (HER2) therapy in primary HER2-overexpressing breast cancer / Sibylle Loibl, Gunter von Minckwitz, Andreas Schneeweiss, Stefan Paepke, Annika Lehmann, Mahdi Rezai,Dirk M. Zahm, Peter Sinn, Fariba Khandan, Holger Eidtmann, Karel Dohnal, Clemens Heinrichs, Jens Huober, Berit Pfitzner, Peter A. Fasching, Fabrice Andre, Judith L. Lindner, Christos Sotiriou, August Dykgers, Sanxing Guo, Stephan Gade, Valentina Nekljudova, Sherene Loi, Michael Untch, and Carsten Denkert" Journal of Clinical Oncology .

Loibl, Sibylle. "PIK3CA Mutations Are Associated With Lower Rates of Pathologic Complete Response to Anti-human Epidermal Growth Factor Receptor 2 (HER2) Therapy in Primary HER2-overexpressing Breast Cancer." Journal of Clinical Oncology 32 (8 September 2014).